1. Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020; 61(3):E304-12. [DOI:10.15167/2421-4248/jpmh2020.61.3.1530] [
DOI:10.18502/ijph.v49i7.3574]
2. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020; 81(2):e16-25. [DOI:10.1016/j.jinf.2020.04.021] [PMID] [PMCID] [
DOI:10.1016/j.jinf.2020.04.021]
3. Kow CS, Hasan SS. Meta-analysis of effect of statins in patients with COVID-19. Am J Cardiol. 2020; 134:153-55. [DOI:10.1016/j.amjcard.2020.08.004] [PMID] [PMCID] [
DOI:10.1016/j.amjcard.2020.08.004]
4. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID Study. Lancet. 2022; 399(10335):1618-24. [DOI:10.1016/S0140-6736(22)00327-0] [PMID] [
DOI:10.1016/S0140-6736(22)00327-0]
5. Hu B, Huang S, Yin L. The cytokine storm and COVID‐19. J Med Virol. 2021; 93(1):250-6. [DOI:10.1002/jmv.26232] [PMID] [PMCID] [
DOI:10.1002/jmv.26232]
6. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020; 11:1708. [DOI:10.3389/fimmu.2020.01708] [PMID] [PMCID] [
DOI:10.3389/fimmu.2020.01708]
7. Pawlos A, Niedzielski M, Gorzelak-Pabiś P, Broncel M, Woźniak E. COVID-19: Direct and indirect mechanisms of statins. Int J Mol Sci. 2021; 22(8):4177. [DOI:10.3390/ijms22084177] [PMID] [PMCID] [
DOI:10.3390/ijms22084177]
8. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. 2013; 99(3):417-35. [DOI:10.1016/j.antiviral.2013.06.018] [PMID] [
DOI:10.1016/j.antiviral.2013.06.018]
9. Çalıca Utku A, Budak G, Karabay O, Güçlü E, Okan HD, Vatan A. Main symptoms in patients presenting in the COVID-19 period. Scott Med J. 2020; 65(4):127-32. [DOI:10.1177/0036933020949253] [PMID] [PMCID] [
DOI:10.1177/0036933020949253]
10. Jean S-S, Hsueh P-R. Old and re-purposed drugs for the treatment of COVID-19. Expert Rev Anti Infect Ther. 2020; 18(9):843-7. [DOI:10.1080/14787210.2020.1771181] [PMID] [PMCID] [
DOI:10.1080/14787210.2020.1771181]
11. Nolan J, Monsieurs K, Bossaert L, Böttiger B, Greif R, Lott C, et al. European Resuscitation Council COVID-19 guidelines executive summary. Resuscitation. 2020; 153:45-55. [doi:10.1016/j.resuscitation.2020.06.001] [
DOI:10.1016/j.resuscitation.2020.06.001]
12. De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tré G, Belmans L, et al. The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents. J Am Med Dir Assoc. 2020; 21(7):909-14.e2. [DOI:10.1016/j.jamda.2020.06.018] [PMID] [PMCID] [
DOI:10.1016/j.jamda.2020.06.018]
13. Davoodi L, Jafarpour H, Oladi Z, Zakariaei Z, Tabarestani M, Ahmadi BM, et al. Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. Int J Cardiol Heart Vasc. 2021; 36:100875. [DOI:10.1016/j.ijcha.2021.100875] [PMID] [PMCID] [
DOI:10.1016/j.ijcha.2021.100875]
14. Tan WYT, Young BE, Lye DC, Chew DEK, Dalan R. Statin use is associated with lower disease severity in COVID-19 infection. Sci Rep. 2020; 10(1):17458. [DOI:10.1038/s41598-020-74492-0] [PMID] [PMCID] [
DOI:10.1038/s41598-020-74492-0]
15. Byttebier G, Belmans L, Alexander M, Saxberg BE, De Spiegeleer B, De Spiegeleer A, et al. Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs. Hum Vaccin Immunother. 2021; 17(9):2841-50. [DOI:10.1080/21645515.2021.1920271] [
DOI:10.1080/21645515.2021.1920271]
16. Zhang X-J, Qin J-J, Cheng X, Shen L, Zhao Y-C, Yuan Y, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020; 32(2):176-87.e4. [DOI:10.1016/j.cmet.2020.06.015] [PMID] [PMCID] [
DOI:10.1016/j.cmet.2020.06.015]
17. Haji Aghajani M, Moradi O, Azhdari Tehrani H, Amini H, Pourheidar E, Hatami F, et al. Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID-19; A retrospective cohort study. Int J Clin Pract. 2021; 75(9):e14434. [DOI:10.1111/ijcp.14434] [PMID] [PMCID] [
DOI:10.1111/ijcp.14434]
18. Bifulco M, Ciccarelli M, Bruzzese D, Dipasquale A, Lania AG, Mazziotti G, et al. The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed. Endocrine. 2021; 71(2):270-2. [DOI:10.1007/s12020-020-02550-8] [PMID] [PMCID] [
DOI:10.1007/s12020-020-02550-8]
19. Hariyanto TI, Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020; 14(6):1613-5. [DOI:10.1016/j.dsx.2020.08.023] [PMID] [PMCID] [
DOI:10.1016/j.dsx.2020.08.023]
20. Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J, et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Cardiol. 2020; 136:149-55. [DOI:10.1016/j.amjcard.2020.09.012] [PMID] [PMCID] [
DOI:10.1016/j.amjcard.2020.09.012]
21. Klok F, Kruip M, Van der Meer N, Arbous M, Gommers D, Kant K, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145-7. [DOI:10.1016/j.thromres.2020.04.013] [PMID] [PMCID] [
DOI:10.1016/j.thromres.2020.04.013]
22. Poor HD, Ventetuolo CE, Tolbert T, Chun G, Serrao G, Zeidman A, et al. COVID‐19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clin Transl Med. 2020; 10(2):e44. [DOI:10.1002/ctm2.44] [PMID] [PMCID] [
DOI:10.1002/ctm2.44]
23. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009; 360(18):1851-61. [DOI:10.1056/NEJMoa0900241] [PMID] [PMCID] [
DOI:10.1056/NEJMoa0900241]
24. Biere-Rafi S, Hutten BA, Squizzato A, Ageno W, Souverein PC, de Boer A, et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J. 2013; 34(24):1800-6. [DOI:10.1093/eurheartj/eht046] [PMID] [
DOI:10.1093/eurheartj/eht046]
25. Arslan F, Pasterkamp G, de Kleijn DP. Unraveling pleiotropic effects of statins: bit by bit, a slow case with perspective. Circ Res. 2008; 103(4):334-6. [DOI:10.1161/CIRCRESAHA.108.182220] [PMID] [
DOI:10.1161/CIRCRESAHA.108.182220]
26. Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, Chung CW, Trelles-Garcia VP, Friedman HJ. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: A retrospective cohort study. Crit Care. 2020; 24(1):429. [DOI:10.1186/s13054-020-03154-4] [PMID] [PMCID] [
DOI:10.1186/s13054-020-03154-4]